16 results about "Membrane Transporters" patented technology

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses a calibrator or a quality control product for an exosome membrane marker detection reagent based on an engineering bacteriophage, the engineering bacteriophage is a bacteriophage capable of simultaneously displaying more than two exosome membrane markers, and the bacteriophage comprises any one of M13, T4, T7 or lambda bacteriophage; the exosome membrane marker comprises at least two of an exosome transmembrane transporter, an exosome specific protein or a disease-related marker. The invention relates to a calibrator or a quality control product for an exosome membrane marker detection reagent based on engineering bacteriophage, which is a low-high-value calibrator or quality control product obtained by diluting the engineering bacteriophage by using a diluent in proportion, and solves the problems of high cell culture and extraction cost, large batch difference, low cost and the like when an exosome is biologically extracted as the calibrator or quality control product for the detection reagent. The problems of poor stability in the use process and the like are solved, and the problems of calibration of a traceable value source and quality control of an exosome membrane marker in-vitro detection kit are solved.

The invention discloses a preparation method of a high-activity mitochondrial targeting MAPS polypeptide preparation, and relates to the technical field of biologication.The preparation method comprises the steps of S1, polypeptide design and synthesis, S2, thiol oriented cross-linking, S3, cutting and purification, S4, liposome assembly and S5, freeze-drying preparation molding.The preparation method has the advantages that by designing an amphipathic alpha-spiral polypeptide structure, the high-activity mitochondrial targeting MAPS polypeptide preparation is obtained; a stable helical conformation is spontaneously formed in a physiological environment by utilizing the alternative arrangement characteristic of hydrophobic and hydrophilic residues; the hydrophobic surface of the conformation can effectively interact with the mitochondrial membrane lipid bilayer, so that the transmembrane resistance is reduced; meanwhile, the hydrophilic surface is combined with the high negative membrane potential of the mitochondrial inner membrane through charge interaction to form a directional driving effect, so that the active transfer efficiency of the polypeptide under the mitochondrial membrane potential is remarkably improved; in addition, the integrated mitochondrial positioning signal further specifically recognizes the mitochondrial outer membrane transporter, the polypeptide is assisted to be accurately anchored to the targeting site, and non-specific diffusion is reduced.

The present invention represents a novel hybrid of the two natural products sclareol and doxorubicin, in the form of their conjugates. These compounds are in the form of conjugates wherein doxorubicin and sclareol are covalently linked by a linker in a molar ratio of 1: 1. The hybrid has been shown to have anti-cancer properties and is effective in the treatment of cancer cells resistant to a P-glycoprotein membrane transporter responsible for resistance to doxorubicin. Hybrid have been tested on different types of cell lines, including human glioblastoma, non-small cell lung cancer, and colorectal cancer. The invention further relates to a method for the production thereof and to the use thereof in pharmaceutical products or pharmaceutical preparations. The research results include the cytotoxic activity of single compounds, combined compounds, and conjugated compounds in sensitive and resistant cancer cell pairs with and without P-glycoprotein expression. The selectivity to cancer cells is determined by comparison with commercially available normal human lung fibroblasts. The study also studies the nanoparticle properties of the hybrids, their intracellular localization and in vivo toxicity.

The present invention provides a tea tree-derived transmembrane transporter gene CsMATE33 and an application thereof, belonging to the technical field of biological breeding. The nucleotide sequence of the tea tree-derived transporter gene CsMATE33 is shown in SEQ ID No. 1. Studies have shown that the tea tree-derived transporter gene CsMATE33 provided by the present invention can increase the content of EGCG in yeast, tea trees and tobacco, and provides valuable gene resources for cultivating high-EGCG plants and microbial varieties, and has good application prospects and value.

The application discloses an Escherichia coli transmembrane transporter gene and application thereof in vitamin B6 biosynthesis. The application weakens a vitamin B6 transporter gene coding in the Escherichia coli, and the ability of a genetically engineered strain to produce vitamin B6 is greatly improved, and the genetically engineered strain has great application and popularization value. In the best embodiment, the extracellular yield of vitamin B6 of the genetically engineered strain is increased by 33.7% compared with that of a wild type, and the effect is extremely remarkable.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

The invention discloses an aromatic compound transporter mutant and application thereof, and belongs to the technical field of bioengineering. The mutant is obtained by carrying out site-specific substitution on a key residue of a gated ring on the basis of an outer membrane transporter derived from Pseudomonas putida, and specifically comprises one or a combination of more of substitution of 120th phenylalanine into glycine, substitution of 121st leucine into glycine and substitution of 122nd glutamine into glycine, and the mutant is obtained by carrying out site-specific substitution on a key residue of a gated ring of the outer membrane transporter, so that the mutant is obtained, and the mutant is obtained by carrying out site-specific substitution on the key residue of the gated ring of the Pseudomonas putida derived from Pseudomonas putida derived from Pseudomonas putida derived from Pseudomonas putida derived from Pseudomonas putida. Preferably, a single mutant F120G, a double mutant F120G / L121G or a three mutant F120G / L121G / Q122G can be included, and conservative substitution derivation can be carried out on the basis of the F120G / L121G / Q122G. The mutant can be used for microbial efficient production and cell tolerance regulation of aromatic compounds according to physicochemical characteristics of a target product, and has important application value in green biological manufacturing, fermentation engineering and bioremediation.

The invention discloses an HlyA secretion system for increasing the secretion amount of substrate protein and a construction method and application thereof.The HlyA secretion system comprises a first component, a second component and a third component, the first component comprises an inner membrane transporter HlyB and a membrane interstitial adaptor protein HlyD, and the inner membrane transporter HlyB and the membrane interstitial adaptor protein HlyD are obtained by expressing modified hlyBD operons; according to the modified hlyBD operon, a nucleotide sequence for coding a hexa-polyhistidine tag is inserted behind an hlyD gene initiation codon in the hlyBD operon; and a second component: an outer membrane channel protein TolC derived from a host cell. According to the invention, the HlyD protein is specifically modified, so that the secretion amount of the HlyA secretion system to the substrate protein is obviously increased.

The invention discloses a 9-hydroxy-androstenedione recombinant mycobacterium capable of improving sterol transport efficiency as well as a construction method and application of the 9-hydroxy-androstenedione recombinant mycobacterium. In original 9-OH-AD mycobacterium neogold, sterol transmembrane transport protein Mce4 and sterol oxidase ChoA are simultaneously overexpressed under the regulation and control of a Pmsp29 promoter, so that the transport efficiency of sterol is improved, a recombinant mycobacterium genetically engineered bacterium capable of efficiently biologically converting phytosterol to prepare 9-OH-AD is constructed, and the fermentation yield is improved by 73.5%. Through optimization research on a 9-OH-AD fermentation conversion system, the feeding amount of a sterol substrate is increased to 12% from 4%, and the feeding amount of the substrate is increased by two times; the dosage of the emulsifier is reduced from 20% to 7%, and the dosage of the emulsifier is reduced by 65%; the fermentation conversion period is shortened from 160 h to 84 h, and the period is shortened by 47.5%; according to the method, the molar conversion rate of the substrate is close to 100% and basically reaches the theoretical conversion rate, the fermentation yield of the 9-OH-AD reaches 86.5 g / L and is improved by 4.2 times, and the fermentation conversion level of the 9-OH-AD is greatly improved.

The invention provides application of cannabidiol in an oligopeptide transporter inhibitor, and particularly belongs to the technical field of membrane transporter inhibitors. The invention provides application of cannabidiol in preparation of an oligopeptide transporter inhibitor, in particular to an oligopeptide transporter inhibitor with non-substrate property. It is found that cannabidiol is an oligopeptide transporter inhibitor with non-substrate properties and can specifically inhibit the substrate uptake ability of an oligopeptide transporter.

This invention discloses an aromatic compound transporter protein mutant and its applications, belonging to the field of bioengineering technology. The mutant is based on *Pseudomonas putida* (…). Pseudomonas putida The outer membrane transport protein derived from [a specific source] is obtained by site-directed substitution of key residues in its gating loop. Specifically, this includes replacing phenylalanine at position 120 with glycine, leucine at position 121 with glycine, and glutamine at position 122 with glycine, or one or more combinations thereof. Preferred mutants include single mutant F120G, double mutant F120G / L121G, or triple mutant F120G / L121G / Q122G, and conserved substitution derivatization can also be performed based on these mutants. These mutants can be used for the efficient microbial production and cell tolerance regulation of aromatic compounds, based on the physicochemical properties of the target product, and have significant application value in green biomanufacturing, fermentation engineering, and bioremediation.

The application discloses application of a transmembrane transporter NPF or SWEET in improving gibberellin yield of Fusarium fujikuroi, and the application comprises the following steps: heterologously expressing an exogenous transmembrane transporter NPF or SWEET in wild-type Fusarium fujikuroi by constructing an integrative expression plasmid, and then improving the gibberellin GA 4+7 yield. The application provides a new idea for improving the gibberellin yield, effectively improves the GA 4+7 yield by heterologously overexpressing the transmembrane transporter NPF or SWEET, and obtains more efficient, more stable, safer and more economically valuable gibberellin, and has a positive promoting effect on industrial production.

The application provides application of cannabidiol in oligopeptide transporter inhibitors and belongs to the technical field of membrane transporter inhibitors. The application provides application of cannabidiol in preparation of oligopeptide transporter inhibitors, in particular, non-substrate oligopeptide transporter inhibitors. It is found that cannabidiol is a non-substrate oligopeptide transporter inhibitor and can specifically inhibit the uptake capacity of oligopeptide transporter to substrates.

The present invention discloses an application of a willow natural resistance-related macrophage protein SsNramp1 in genetic engineering for cadmium-contaminated soil remediation. The willow SsNramp1 in the present invention has the activity of transporting cadmium, and SsNramp1 is a membrane transport protein located on the cytoplasmic membrane. After SsNramp1 is activated to express the protein in tobacco using Agrobacterium tumefaciens-mediated genetic transformation technology and a 35S strong promoter, the growth of tobacco transfected with the SsNramp1 gene is not significantly affected under a cadmium exposure environment compared with the wild type, while the cadmium concentration in the root system increases by 64%-128%, and the cadmium concentration in the aboveground part increases by 35%-51%. The present invention illustrates that willow SsNramp1 is of great significance in cadmium-contaminated soil remediation engineering.

The present invention provides a tea plant-derived transmembrane transporter gene, CsMATE40, a recombinant expression vector, a genetically engineered bacterium, and applications thereof, belonging to the field of plant genetic engineering technology. The nucleotide sequence of the tea plant-derived transmembrane transporter gene, CsMATE40, is shown in SEQ ID No. 1. Experimental results show that the tea plant-derived transmembrane transporter gene, CsMATE40, can increase the accumulation of epicatechin and the expression of genes related to epicatechin synthesis in host plants. These results demonstrate that the present invention provides an excellent candidate gene for breeding new high-epicatechin plant varieties, possessing potential for application and significant value prospects.